Nicole Moore, NP
Adult Health · New Albany, INNPI 1700149101
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 517 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 28.5% of the total. 2025 is the largest year on record at $2,568, 2.2 times the $1,161 reported in 2021. Among adult health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$900
- Johnson & Johnson$610
- Sanofi$350
- QOL Medical, LLC$310
- plus $3K from 31 others
What the payments were for
- Consulting fees$1402%
- Food & beverage$8,10498%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 164 | $2,367 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 75 | $1,009 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $900 |
| Johnson & Johnson | 35 | $610 |
| Sanofi | 17 | $350 |
| QOL Medical, LLC | 15 | $310 |
| Pfizer | 20 | $307 |
| Phathom Pharmaceuticals, Inc. | 18 | $271 |
| Gilead | 15 | $268 |
| Ardelyx, Inc. | 17 | $267 |
| Regeneron Healthcare Solutions, Inc. | 10 | $200 |
| Medtronic | 1 | $140 |
| Boston Scientific | 5 | $132 |
| Intercept Pharmaceuticals, Inc. | 8 | $129 |
| Merck | 7 | $119 |
| Celltrion USA Inc. | 6 | $103 |
| Aimmune Therapeutics, Inc. | 3 | $79 |
| Novo Nordisk | 4 | $76 |
| Ironwood Pharmaceuticals, Inc | 4 | $66 |
| Bristol Myers Squibb | 4 | $66 |
| Amgen | 4 | $64 |
| Ipsen Biopharmaceuticals, Inc | 4 | $60 |
| Madrigal Pharmaceuticals | 3 | $60 |
| Organon | 6 | $60 |
| Tersera Therapeutics LLC | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| Fresenius Kabi USA, LLC | 2 | $31 |
| Mylan Institutional Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Vivus LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| CSL Behring | 1 | $15 |
| Sandoz | 1 | $13 |
| Evoke Pharma, Inc. | 1 | $12 |
| Endogastric Solutions, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,298 in reported general payments places this provider in the 95th percentile of 391 adult health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 110 | $118,894 |
| Humira(Cf) PenAdalimumab | 14 | $97,615 |
| CreonLipase/Protease/Amylase | 18 | $52,130 |
| XifaxanRifaximin | 16 | $48,685 |
| MotegrityPrucalopride Succinate | 44 | $29,686 |
| MovantikNaloxegol Oxalate | 25 | $14,976 |
| Colestipol Hcl | 73 | $9,178 |
| Lubiprostone | 45 | $5,974 |
| Mesalamine | 13 | $5,546 |
| Dicyclomine Hcl | 240 | $5,032 |
| Mesalamine ErMesalamine | 18 | $4,805 |
| Pantoprazole Sodium | 337 | $4,438 |
| Ursodiol | 28 | $3,883 |
| Famotidine | 283 | $3,276 |
| Sucralfate | 76 | $1,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $2,367 | $171,024128 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,009 | $48,68516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $900 | $29,68644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 adult health providers in Indiana.
Other adult health in New Albany
- Chelsea KellamsNew Albany$8K
- Kimberly RobertsonNew Albany$5K
- Lauren EurtonNew Albany$3K
- Jennifer BerryIndianapolis$50K
- Tajuana DavisZionsville$31K
- Patricia Damron-RobinsonMerrillville$20K
- Terry RidgeCarmel$20K
- Kristine StarcevichMerrillville$19K
- Jolyn Holliday VezaGreenfield$17K
- Anna MatulewiczMishawaka$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.